AbbVie Inc. $ABBV Shares Bought by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lifted its position in AbbVie Inc. (NYSE:ABBV) by 87.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,375 shares of the company’s stock after buying an additional 61,000 shares during the period. AbbVie comprises 3.3% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 3rd largest position. Rhenman & Partners Asset Management AB’s holdings in AbbVie were worth $30,187,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ABBV. Munich Reinsurance Co Stock Corp in Munich bought a new position in AbbVie during the third quarter worth about $47,597,000. Angeles Wealth Management LLC raised its position in shares of AbbVie by 3.1% during the third quarter. Angeles Wealth Management LLC now owns 14,886 shares of the company’s stock worth $3,447,000 after purchasing an additional 448 shares during the period. Blair William & Co. IL lifted its holdings in shares of AbbVie by 0.5% during the 3rd quarter. Blair William & Co. IL now owns 1,263,581 shares of the company’s stock valued at $292,570,000 after purchasing an additional 6,169 shares in the last quarter. Baltimore Washington Financial Advisors Inc. grew its position in shares of AbbVie by 3.5% in the 3rd quarter. Baltimore Washington Financial Advisors Inc. now owns 1,790 shares of the company’s stock valued at $414,000 after purchasing an additional 60 shares during the period. Finally, Ramirez Asset Management Inc. raised its holdings in AbbVie by 6.9% during the 3rd quarter. Ramirez Asset Management Inc. now owns 23,547 shares of the company’s stock worth $5,452,000 after buying an additional 1,520 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 0.8%

Shares of ABBV stock opened at $230.41 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company’s fifty day simple moving average is $224.72 and its 200-day simple moving average is $224.10. The firm has a market cap of $407.40 billion, a PE ratio of 97.63, a P/E/G ratio of 0.80 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the firm earned $2.16 earnings per share. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY/Q1 outlook — AbbVie posted better‑than‑expected Q4 EPS and revenue and gave FY‑2026 guidance (14.37–14.57 EPS), supporting the bull case for continued top‑line and EPS growth. AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?
• Positive Sentiment: Pipeline catalysts: neuroscience momentum and new approvals could drive revenue — the neuroscience unit generated ~$10.8B in 2025 and analysts see upside to ~$12.5B in 2026 as Vyalev ramps and tavapadon awaits FDA review. Will AbbVie’s Neuroscience Segment Continue to Aid Top Line in 2026?
• Positive Sentiment: Positive Phase‑3 SKYRIZI Crohn’s data strengthens the immunology franchise and expands commercial potential for risankizumab. This data is a material upside to long‑term revenue expectations for immunology products. Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
• Neutral Sentiment: Analyst/market attention: some bullish writeups call ABBV a core, buy‑and‑hold dividend name and note the stock has rallied since earnings — supportive for sentiment but already reflected in recent gains. AbbVie: The only big pharma stock I’d consider a buy-and-never-sell
• Neutral Sentiment: Operational investment: AbbVie will spend $380M to expand its North Chicago campus — a long‑term capacity/R&D bet that supports future growth but increases near‑term capex. AbbVie to invest $380 million in North Chicago campus to make next generation medicines
• Negative Sentiment: Debt issuance: AbbVie completed an $8B senior notes offering, which increases leverage and raises capital‑structure risk that investors may price in, especially given the company’s already elevated payout metrics. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Negative Sentiment: Dividend and leverage concerns: analysts caution that a very high payout ratio and significant debt levels warrant caution for income investors despite strong free cash flow. That raises risk of multiple compression if growth slows. Dividend Stock Analysis – Abbvie Inc.
• Negative Sentiment: Near‑term price pressure: recent sessions show ABBV underperforming the wider market on profit‑taking and macro moves, which can amplify volatility after the post‑earnings run. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ABBV. Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. Scotiabank began coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Finally, UBS Group dropped their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.